RxDoctor Payments Data

Taylor Currall, PA

Physician Assistant · Shallotte, NCNPI 1306328588

Payments from drug & device makers

$1,720in general payments, 2019–2025

Across 66 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$533
  • Johnson & Johnson$232
  • Lilly USA, LLC$152
  • AstraZeneca$114
  • Novo Nordisk$105
  • Amgen$99
  • plus $486 from 14 others

What the payments were for

  • Food & beverage$1,720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,720 in reported general payments places this provider in the 75th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$57,678
Medicare patients
258
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide223$386,132
Xultophy 100-3.6Insulin Degludec/Liraglutide114$215,259
MounjaroTirzepatide105$152,446
JardianceEmpagliflozin120$138,370
TrulicityDulaglutide74$118,821
FarxigaDapagliflozin Propanediol91$81,580
Soliqua 100-33Insulin Glargine/Lixisenatide61$71,624
Humulin R U-500 KwikpenInsulin Regular, Human60$66,815
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/748$64,462
Tresiba Flextouch U-200Insulin Degludec57$63,842
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog48$59,364
Tresiba Flextouch U-100Insulin Degludec84$58,396
RybelsusSemaglutide35$57,804
FiaspInsulin Aspart (Niacinamide)15$22,915
JanuviaSitagliptin Phosphate19$22,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog$105$696,997423 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$152$281,564207 claims
AstraZenecaFarxiga$114$81,58091 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$34$71,62461 claims
Johnson & JohnsonInvokana$232$9,35714 claims
AbbVieSynthroid$34$4,65367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Shallotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →